American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006

Clark, Mike; Colombel, Jean Fréd́eric; Feagan, Brian; Fedorak, Richard N.; Hanauer, Stephen B.; Kamm, Michael A.; Mayer, Lloyd; Regueiro, Carol; Rutgeerts, Paul; Sandborn, William J.; Sands, Bruce E.; Schreiber, Stefan; Targan, Stephan R.; Travis, Simon; Vermeire, Séverine

doi:10.1053/j.gastro.2007.05.006

Cited by 202 publications

(138 citation statements)

References 96 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…For patients who initially respond, but then begin to lose their response aft er a number of infusions, increasing the dose to 10 mg / kg, or shortening the interval between doses, may improve the likelihood of success (although this strategy was not studied in a controlled manner in the ACT 1 and 2 studies). Patients who do not respond to a dose as high as 10 mg / kg as oft en as every 4 weeks should not be continued on the drug ( 156 ).…”

Section: Infl Iximabmentioning

confidence: 99%

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Kornbluth

Sachar

2010

American Journal of Gastroenterology

1,140

977

View full text Add to dashboard Cite

Guidelines for clinical practice are aimed to indicate preferred approaches to medical problems as established by scientifi cally valid research. Double-blind placebo controlled studies are preferable, but compassionate-use reports and expert review articles are used in a thorough review of the literature conducted through Medline with the National Library of Medicine. When only data that will not withstand objective scrutiny are available, a recommendation is identifi ed as a consensus of experts. Guidelines are applicable to all physicians who address the subject regardless of specialty training or interests and are aimed to indicate the preferable but not necessarily the only acceptable approach to a specifi c problem. Guidelines are intended to be fl exible and must be distinguished from standards of care, which are infl exible and rarely violated. Given the wide range of specifi cs in any healthcare problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision. Guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the board of trustees. Each has been intensely reviewed and revised by the Committee, other experts in the fi eld, physicians who will use them, and specialists in the science of decision analysis. The recommendations of each guideline are therefore considered valid at the time of composition based on the data available. New developments in medical research and practice pertinent to each guideline will be reviewed at a time established and indicated at publication to assure continued validity. The recommendations made are based on the level of evidence found. Grade A recommendations imply that there is consistent level 1 evidence (randomized controlled trials), grade B indicates that the evidence would be level 2 or 3, which are cohort studies or case -control studies. Grade C recommendations are based on level 4 studies, meaning case series or poor-quality cohort studies, and grade D recommendations are based on level 5 evidence, meaning expert opinion.

show abstract

Section: Infl Iximabmentioning

confidence: 99%

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Kornbluth

Sachar

2010

American Journal of Gastroenterology

1,140

977

View full text Add to dashboard Cite

show abstract

“…IBD patients are frequently treated with immunosuppressive agents, including corticosteroids, cyclosporine, azathioprine and methotrexate, either alone or in combination (7,8). Therefore, severe or refractory IBD patients are thought to be at an increased risk of infection with CMV.…”

Section: Discussionmentioning

confidence: 99%

Toxic Megacolon Associated with Cytomegalovirus Infection in a Patient with Steroid-naïve Ulcerative Colitis

et al. 2012

View full text Add to dashboard Cite

Most cases of cytomegalovirus (CMV) colitis in patients with inflammatory bowel disease (IBD) occur in those treated with immunosuppressants and/or corticosteroids. We herein present the case of a 57-year-old man with toxic megacolon associated with CMV colitis in corticosteroid-naïve ulcerative colitis (UC). To date, there have been only eight previous case reports of CMV colitis in steroid-naïve UC. We discuss the need to consider CMV colitis when making a differential diagnosis of patients with refractory UC who are not receiving corticosteroid treatment.

show abstract

“…Hence recent initiation of infliximab can identify recently active disease even though long term usage does not 20 . Participants were asked whether they had used any of these medications in the previous six months, including number of weeks of use and maximum daily dosage.…”

Section: Biological Markers and Medication Usementioning

confidence: 99%

The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity

et al. 2009

View full text Add to dashboard Cite

show abstract

American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006

Cited by 202 publications

References 96 publications

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Toxic Megacolon Associated with Cytomegalovirus Infection in a Patient with Steroid-naïve Ulcerative Colitis

The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity

Contact Info

Product

Resources

About